Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms:

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $73 | In Stock | In Stock | |
| 2 mg | $107 | In Stock | In Stock | |
| 5 mg | $179 | In Stock | In Stock | |
| 10 mg | $287 | In Stock | In Stock | |
| 25 mg | $539 | In Stock | In Stock | |
| 50 mg | $769 | In Stock | In Stock | |
| 100 mg | $1,050 | In Stock | In Stock | |
| 200 mg | $1,410 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $190 | In Stock | In Stock |
| Description | GSK3685032 is a time-independent, non-covalent, selective, and reversible DNMT1 inhibitor with an IC₅₀ of 0.036 μM. GSK3685032 induces loss of DNA methylation, transcriptional activation, and inhibition of cancer cell growth, and can be used in cancer therapy research. |
| Targets & IC50 | DNMT1:36 nM, MM.IR cells:0.64 μM, Ki-JK cells:0.64 μM, EOL-1 cells:0.64 μM |
| In vitro | Methods: HCT-116 cells were treated with GSK3685032 at gradient concentrations (0.1 μM, 1 μM, 10 μM) for 72 hours, followed by DNA methylation level detection via sulfite sequencing. Results: GSK3685032 dose-dependently reduced global and promoter region DNA methylation. [1] Methods: Wild-type mESCs were treated with 2 μM and 10 μM GSK3685032 for 2, 4, 6, 8, 10, 12, and 14 days. RT-qPCR was used to detect genes known to be regulated by methylation. Results: Significant upregulation of methylation-regulated genes was observed after just 2 days of GSK3685032 treatment. [2] |
| In vivo | Methods: MV-4-11 AML cells were subcutaneously implanted into nude mice. After tumors became palpable, mice were randomly assigned to treatment groups. GSK3685032 was administered orally once daily at doses of 25, 50, and 100 mg/kg for 21 days. Results: GSK3685032 exhibited dose-dependent inhibition of tumor growth and induced tumor regression at the 100 mg/kg dose. [1] |
| Molecular Weight | 420.53 |
| Formula | C22H24N6OS |
| Cas No. | 2170137-61-6 |
| Smiles | CCc1c(C#N)c(SC(C(N)=O)c2ccccc2)nc(N2CCC(N)CC2)c1C#N |
| Relative Density. | 1.33 g/cm3 (Predicted) |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 26.4 mg/mL (62.78 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.76 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.